The Limited Times

Now you can see non-English news...

The American IRA law, a shock for global pharma


DECRYPTION - The major laboratories could be forced to rethink their R&D, at the risk of weighing on innovation.

Tags: IRA, Inflation, Big PharmaBy: Keren Lentschner

The Sanofi laboratory has announced a 78% price drop for its best-selling insulin in the United States.

The list of culprits fell on Wednesday.

They are 27 drugs, pinned by the White House, because the increase in their prices exceeded inflation in the 4th quarter of 2022. Pfizer is the last of the class, with 5 drugs concerned.

Laboratories will have to pay rebates to the US government.

These measures are part of the Inflation Reduction Act (IRA), passed last summer, which will gradually come into force in the United States by 2029. Legislation that is disrupting the pharmaceutical industry.

Although there has been much talk in Europe of the consequences of the IRA on the industry of the Old Continent, its health component has attracted less attention.

The ambition of the Biden Administration is to reduce inequalities in access to care in the United States, in particular by lowering drug prices while…

This article is for subscribers only.

You have 87% left to discover.

Want to read more?

Unlock all items immediately.

Without engagement.

TEST FOR €0.99

Already subscribed?


Source: lefigaro

All business articles on 2023-03-17

You may like

News/Politics 2023-02-06T19:43:45.792Z

Trends 24h

Business 2023-03-26T08:18:00.674Z


© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.